Promising evidence about the “bone fracture problem” with semaglutide is emerging.

June 2026 | Clinical Commentary
Author: Dr Keifer Walsh
One of the major concerns in obesity medical management has been the potential effect of rapid, significant weight loss on bone mineral density. A new real-world study presented at ENDO 2026 – The Endocrine Society’s annual meeting – offers some reassuring and clinically relevant data on this front, specifically for patients on semaglutide (Ozempic, Wegovy, Rybelsus).

About the study

Researchers led by Dr. Jairo Noreña at Stanford University Medical Center conducted a large retrospective cohort study using the Atropos Health Eos EHR database, capturing data from over 161 million patients across U.S. community and academic medical centers from 2016-2023. The analysis included nearly 60,000 adults with type 2 diabetes who had no prior fracture history and no prior use of osteoporosis medications.
The semaglutide group (n = 26,324) was compared against patients on dulaglutide, phentermine/topiramate, or bupropion/naltrexone (n = 33,555). The results were notable on two fronts: semaglutide users lost more weight (greater BMI reduction) yet experienced fewer fractures (794 versus 1,045 in the comparator group), translating to approximately a 15% lower fracture risk. This is a counterintuitive finding given the prevailing assumption that more aggressive weight loss carries higher skeletal risk.
The authors appropriately note that this is an observational study and that prospective data will be needed to confirm causality, but the magnitude and consistency of the signal across a very large dataset makes it worth paying attention to now.

Other things that we know

The concern that GLP-1 receptor agonists might compromise bone health has been on the radar for years. Earlier research, including analyses of GLP-1 use in type 2 diabetes cohorts, raised the theoretical worry that rapid fat mass reduction – which typically precedes muscle and structural adaptation – could accelerate bone turnover and reduce density. Some data on older GLP-1 agents suggested modest effects on bone remodeling markers.
However, the emerging literature on semaglutide specifically has been more reassuring. The SELECT trial demonstrated a 20% reduction in major adverse cardiovascular events in non-diabetic overweight and obese patients, hinting at pleiotropic systemic benefits beyond glycemic and weight outcomes. More recently, studies have explored semaglutide’s associations with reduced cancer risk, lower rates of depression and anxiety, and even reduced addiction-related outcomes — suggesting the drug may be exerting favorable effects across multiple organ systems through mechanisms not yet fully characterized.
Regarding bone specifically, one hypothesis worth exploring is that GLP-1 receptors are expressed in osteoblasts, and direct receptor-mediated activity may offer some degree of skeletal protection independent of weight loss magnitude. Whether this biological plausibility holds up in prospective mechanistic studies remains to be seen.

What this means

This provides reassurance, but not complacency. Though this study provides real-world signal that semaglutide likely does not increase fracture risk compared to other anti-obesity agents, a thoughtful approach to exercise and nutrition, and consideration of monitoring parameters are still important. Preserving lean mass during weight loss is the best-studied strategy for maintaining bone density, and recent data suggesting reduced physical activity among GLP-1 users makes this conversation more urgent, not less. Bone health monitoring still matters. The study authors specifically call for monitoring bone health in weight-loss programs. Baseline DEXA screening and comprehensive laboratory assessment should still be considered for most patients.
Context matters for comparators. The comparator agents in this study include older oral medications (phentermine/topiramate, bupropion/naltrexone) as well as another GLP-1 (dulaglutide). Semaglutide outperformed all of them on both weight loss and fracture outcomes – useful information when choosing between agents for an appropriate candidate.
The evidence base for semaglutide continues to mature, and the skeletal safety profile is looking increasingly favorable. Stay tuned for prospective data, but for now, this is one more reason to feel confident prescribing it — appropriately selected — for your patients pursuing meaningful weight loss.

The bottom line

This large real-world study adds meaningful reassurance that semaglutide does not appear to compromise bone health during weight loss (and may actually reduce fracture risk) compared to other anti-obesity agents, even when patients lose more weight. While prospective data are still needed to confirm causality, the signal is consistent and clinically relevant. For now, skeletal concerns should not be a barrier to considering semaglutide for appropriate candidates, though baseline bone health assessment and resistance exercise counseling remain essential components of comprehensive weight management care.

Sources

Endocrine Society. (2026, June 14). Semaglutide linked to lower bone fracture risk [Press release]. https://www.endocrine.org/news-and-advocacy/news-room/2026/jairo-norena-press-release-endo-2026.
Hendershot, C. S., Bremmer, M. P., Paladino, M. B., et al. (2025). Once-weekly semaglutide in adults with alcohol use disorder: A randomized clinical trial. JAMA Psychiatry, 82(4), 395–405. https://doi.org/10.1001/jamapsychiatry.2024.4789.
Kim, D. D., Silverman, M. N., Lee, S., & McIntyre, R. S. (2026). Association between GLP-1 receptor agonist use and worsening mental illness in people with depression and anxiety in Sweden: a national cohort study. The Lancet Psychiatry. Advance online publication. https://doi.org/10.1016/S2215-0366(26)00014-3
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., et al. (2023). Semaglutide and cardiovascular outcomes in obesity without diabetes. New England Journal of Medicine, 389(24), 2221–2232. https://doi.org/10.1056/NEJMoa2307563.